nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00897117,Molecular Fingerprinting of Lung Cancer,,Recruiting,Observational,Lung Cancer,gene expression analysis; microarray analysis; protein expression analysis; biologic sample preservation procedure; laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry,,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),4000,2001-05-05,2031-05-31,United States,No,https://clinicaltrials.gov/study/NCT00897117
NCT02143830,"A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine",Phase 2,Recruiting,Interventional,Fanconi Anemia; Severe Marrow Failure; Myelodysplastic Syndrome (MDS); Acute Myelogenous Leukemia (AML),Busulfan; Cyclophosphamide; Fludarabine; rabbit ATG; G-CSF; Peripheral blood stem cell,,"Children's Hospital Medical Center, Cincinnati",Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center,70,2014-04-05,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT02143830
NCT02570815,Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer: Analysis of Accuracy and Added Value,Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer,indocyanine green,,St. Joseph's Healthcare Hamilton,,250,2016-10-05,2026-12-05,Canada,No,https://clinicaltrials.gov/study/NCT02570815
NCT03260491,"A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),HER3-DXd (FL-DP); HER3-DXd (CTM-1 Lyo-DP); HER3-DXd (CTM-3 Lyo-DP),,Daiichi Sankyo,Merck Sharp & Dohme LLC,309,2017-10-30,2026-12-31,Japan; Netherlands; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT03260491
NCT03420963,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,Phase 1,Recruiting,Interventional,Recurrent Cutaneous Melanoma; Recurrent Lip and Oral Cavity Carcinoma; Recurrent Malignant Endocrine Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Male Reproductive System Neoplasm; Recurrent Malignant Mesothelioma; Recurrent Malignant Neoplasm of Multiple Primary Sites; Recurrent Malignant Oral Neoplasm; Recurrent Malignant Pharyngeal Neoplasm; Recurrent Malignant Skin Neoplasm; Recurrent Malignant Soft Tissue Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Thyroid Gland Neoplasm; Recurrent Malignant Urinary System Neoplasm; Refractory Cutaneous Melanoma; Refractory Malignant Bone Neoplasm; Refractory Malignant Endocrine Neoplasm; Refractory Malignant Female Reproductive System Neoplasm; Refractory Malignant Male Reproductive System Neoplasm; Refractory Malignant Mesothelioma; Refractory Malignant Neoplasm of Multiple Primary Sites; Refractory Malignant Oral Neoplasm; Refractory Malignant Pharyngeal Neoplasm; Refractory Malignant Skin Neoplasm; Refractory Malignant Soft Tissue Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Malignant Thyroid Gland Neoplasm; Refractory Malignant Urinary System Neoplasm,Cord Blood-derived Expanded Allogeneic Natural Killer Cells; Cyclophosphamide; Etoposide,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),38,2018-08-31,2027-12-01,United States,No,https://clinicaltrials.gov/study/NCT03420963
NCT03551951,"Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening",,Recruiting,Observational,Non Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Hepatocellular Cancer; Colorectal Cancer,"Test for circulating tumor cells, DNA alterations",,University of Missouri-Columbia,Harry S. Truman Memorial Veterans' Hospital,320,2016-07-01,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT03551951
NCT03851445,LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study),Phase 2/Phase 3,Recruiting,Interventional,Previously Treated Non-Small Cell Lung Cancer,Screening Platform,,SWOG Cancer Research Network,National Cancer Institute (NCI),10000,2019-02-06,2029-01-28,United States,No,https://clinicaltrials.gov/study/NCT03851445
NCT04151342,CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS),,Recruiting,Observational,"Cancer; Malignancies Multiple; Malignant Solid Tumor; Cancer, Therapy-Related; Molecular Sequence Variation; Genetic Alteration; Gene Fusion; Receptor Tyrosine Kinase Gene Mutation; RTK Family Gene Mutation; Ras (Kras or Nras) Gene Mutation",Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.; Patient-reported outcomes (PROs),,"University Health Network, Toronto","Takeda Canada, Inc.; Applied Health Research Centre; Programs for Assessment of Technology in Health Research Institute; AstraZeneca; Amgen; Bayer; Nuvation Bio Inc.; IQVIA Solutions Canada Inc.",5500,2020-01-17,2029-12-05,Canada,No,https://clinicaltrials.gov/study/NCT04151342
NCT04155034,MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK),Phase 3,Recruiting,Interventional,Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma,Magnetic Resonance Imaging; Prophylactic Cranial Irradiation,,SWOG Cancer Research Network,National Cancer Institute (NCI),668,2020-05-04,2029-11-15,Canada; Chile; Colombia; Mexico; Saudi Arabia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04155034
NCT04165070,"KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)",Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Pembrolizumab; Carboplatin; Paclitaxel; Pemetrexed; Vibostolimab; Boserolimab; MK-4830; MK-0482; Ifinatamab Deruxtecan (I-DXd); HER3-DXd,,Merck Sharp & Dohme LLC,Daiichi Sankyo,450,2019-12-19,2032-02-13,Hungary; Israel; Italy; Poland; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04165070
NCT04235114,Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR Positive Cancers by Positron Emission Tomography (PET),Phase 1/Phase 2,Recruiting,Interventional,Lung Cancer; Colorectal Cancer,50 mg 89Zr-DFO-Nimotuzumab; 1 mg 89Zr-DFO-Nimotuzumab,,University of Saskatchewan,,14,2020-02-01,2026-12-05,Canada,No,https://clinicaltrials.gov/study/NCT04235114
NCT04302025,"NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib,,"Genentech, Inc.",,99,2020-11-06,2030-05-30,United States,No,https://clinicaltrials.gov/study/NCT04302025
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04423029,"A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",Phase 1,Recruiting,Interventional,Solid Tumors,DF6002; Nivolumab,,Dragonfly Therapeutics,,438,2020-07-13,2027-11-30,Australia; France; Spain; United States,No,https://clinicaltrials.gov/study/NCT04423029
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Phase 2,Recruiting,Interventional,Solid Tumors,Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib,,Hoffmann-La Roche,,920,2021-01-18,2032-09-25,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; New Zealand; Poland; Portugal; Puerto Rico; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04589845
NCT04613596,A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2/Phase 3,Recruiting,Interventional,Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer,Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab,,Mirati Therapeutics Inc.,,806,2020-12-02,2029-10-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Georgia; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Norway; Peru; Philippines; Poland; Portugal; Romania; Serbia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04613596
NCT04665206,"Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult; Mesothelioma; NSCLC",VT3989; Nivolumab & Ipilimumab; Osimertinib,,"Vivace Therapeutics, Inc",,336,2021-03-24,2027-06-02,Australia; United States,No,https://clinicaltrials.gov/study/NCT04665206
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04871412,Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care - The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial - Stage III,Phase 3,Recruiting,Interventional,Lung Cancer; Gastric Cancer; Esophageal Cancer,Vitamin D3 Drops; Coriolus Versicolor; Trident SAP 66:33 Lemon; Probiotic Pro12; Provitalix Pure Whey Protein; Theracurmin 2X; Green Tea Extract; Nutrition Recommendations; Physical Activity Recommendations; Psychological Recommendations,,Ottawa Hospital Research Institute,The Canadian College of Naturopathic Medicine; Lotte & John Hecht Memorial Foundation; The Centre for Health Innovation; University of Ottawa,20,2022-04-04,2029-12-01,Canada,No,https://clinicaltrials.gov/study/NCT04871412
NCT04929223,"A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",Phase 1,Recruiting,Interventional,Metastatic Colorectal Cancer,Inavolisib; Bevacizumab; Cetuximab; Atezolizumab; Tiragolumab; SY-5609; Divarasib; FOLFOX; FOLFIRI; FoundationOne®Liquid CDx,,Hoffmann-La Roche,,542,2021-10-22,2028-11-07,Australia; Canada; Denmark; Germany; Italy; Poland; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04929223
NCT04956640,A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms",LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin,,Eli Lilly and Company,Merck Sharp & Dohme LLC,540,2021-07-19,2027-04-05,Australia; Canada; France; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04956640
NCT05058651,Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC),Phase 2/Phase 3,Recruiting,Interventional,Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma,Atezolizumab; Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Etoposide; Magnetic Resonance Imaging; Patient Observation,,National Cancer Institute (NCI),,189,2022-06-28,2028-10-01,United States,No,https://clinicaltrials.gov/study/NCT05058651
NCT05067283,"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,MK-1084; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil,,Merck Sharp & Dohme LLC,,830,2021-12-17,2030-02-25,Australia; Canada; Chile; China; Denmark; Israel; Italy; Japan; Lithuania; Malaysia; New Zealand; Panama; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05067283
NCT05074810,A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; KRAS Activating Mutation,avutometinib and sotorasib; avutometinib and sotorasib and defactinib,,"Verastem, Inc.",Amgen,153,2022-04-12,2027-04-05,Belgium; France; Netherlands; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05074810
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05254184,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,12,2022-11-01,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT05254184
NCT05394831,"A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,EGFR Mutant Advanced Non-small Cell Lung Cancer,JIN-A02,,J Ints Bio,,150,2023-07-30,2026-09-30,South Korea; Thailand; United States,No,https://clinicaltrials.gov/study/NCT05394831
NCT05410145,"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,KRAS P.G12C,D3S-001; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Cetuximab,,"D3 Bio (Wuxi) Co., Ltd",,442,2022-08-03,2027-04-05,Australia; China; France; Germany; Hong Kong; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05410145
NCT05415358,A Prospective Study Of Immune Signatures In Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients At Completion Of Immune Checkpoint Inhibitor Treatment Either As Monotherapy Or In Combination With Chemotherapy In The First Line Setting,,Recruiting,Observational,"Lung Cancer, Nonsmall Cell",Blood and tissue samples,,Wake Forest University Health Sciences,Atrium Health Levine Cancer Institute; Atrium Health Wake Forest Baptist,23,2023-01-17,2035-09-05,United States,No,https://clinicaltrials.gov/study/NCT05415358
NCT05430009,Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Liver Metastases; Non-small Cell Lung Cancer,Liver SBRT; Pembrolizumab,,VA Ann Arbor Healthcare System,LUNGevity Foundation,12,2022-06-17,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT05430009
NCT05443126,"A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; NSCLC,EP0031,,Ellipses Pharma,,265,2022-09-30,2027-06-05,France; Spain; United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05443126
NCT05501665,SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study,Phase 1/Phase 2,Recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer,Biospecimen Collection; Carboplatin; Computed Tomography; Fludeoxyglucose F-18; Nab-paclitaxel; Pembrolizumab; Pemetrexed; Positron Emission Tomography; Radiation Therapy; [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan; Ipilimumab; Nivolumab; Cemiplimab; Atezolizumab,,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI); Varian Medical Systems,25,2023-05-09,2027-02-01,United States,No,https://clinicaltrials.gov/study/NCT05501665
NCT05519293,"A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,H002,,RedCloud Bio,Parexel,76,2022-12-15,2025-02-28,United States,No,https://clinicaltrials.gov/study/NCT05519293
NCT05609578,A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced NSCLC; Metastatic Lung Cancer,Adagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin,,Mirati Therapeutics Inc.,,90,2022-11-22,2026-12-01,Brazil; Chile; France; Georgia; Greece; Hungary; Italy; Malaysia; Poland; Serbia; Spain; Switzerland; Thailand; United States,No,https://clinicaltrials.gov/study/NCT05609578
NCT05638295,A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial,Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Panitumumab; Sotorasib,,National Cancer Institute (NCI),,105,2024-08-01,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05638295
NCT05671510,"Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors",Phase 3,Recruiting,Interventional,Non Small Cell Lung Cancer,Gotistobart; Docetaxel,,"OncoC4, Inc.",BioNTech SE,600,2023-06-28,2027-06-30,Australia; Belgium; Canada; China; Germany; Italy; Netherlands; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05671510
NCT05684965,"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,XTX301,,"Xilio Development, Inc.",,358,2023-05-11,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05684965
NCT05715229,A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed,,Hackensack Meridian Health,MedSIR,108,2023-09-29,2026-04-28,United States,No,https://clinicaltrials.gov/study/NCT05715229
NCT05736029,"PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.",,Recruiting,Observational,Non Small Cell Lung Cancer; Healthy,"blood, stool and tissue samples collection",,OncoHost Ltd.,,350,2022-11-07,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05736029
NCT05738252,Frailty Assessments for Risk Assessment in Gynecologic Oncology Patients Undergoing Surgery and Chemotherapy,,Recruiting,Observational,Gynecologic Cancer; Frailty; Oncology,Clinical Frailty Scale; Frailty Phenotype,,Population Health Research Institute,,280,2023-06-15,2025-10-05,Canada,No,https://clinicaltrials.gov/study/NCT05738252
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05789082,"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer,Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed,,Hoffmann-La Roche,,320,2023-06-20,2032-01-29,Argentina; Australia; Belgium; Brazil; Canada; China; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05789082
NCT05799274,Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors,Phase 1,Recruiting,Interventional,Healthy Volunteers; Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Esophageal Squamous Cell Carcinoma; Cervical Cancer; Endometrial Cancer; Ovarian Cancer,RAD301 ([68Ga]-RAD301),,"Radiopharm Theranostics, Ltd",,9,2023-11-09,2025-11-05,United States,No,https://clinicaltrials.gov/study/NCT05799274
NCT05800587,Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities,Phase 2,Recruiting,Interventional,Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer,Carboplatin; Pemetrexed; Paclitaxel; Nab paclitaxel; Docetaxel; Gemcitabine; Etoposide; Irinotecan; Topotecan; Lurbinectedin,,Fox Chase Cancer Center,,280,2023-02-22,2029-08-01,United States,No,https://clinicaltrials.gov/study/NCT05800587
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05866302,"Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients. A Multi-center, Observational Trial.",,Recruiting,Observational,Chronic Lung Disease; Hematopoietic Cell Transplantation; Graft Versus Host Disease,,,University of Michigan Rogel Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)",375,2023-05-30,2028-05-05,United States,No,https://clinicaltrials.gov/study/NCT05866302
NCT05920356,"A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),Sotorasib; Pembrolizumab,,Amgen,,750,2023-11-16,2031-06-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05920356
NCT05985655,"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Breast Carcinoma; High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC); Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",GTAEXS617; SoC,,"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",,165,2023-07-06,2028-05-05,Belgium; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05985655
NCT06026410,"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC),Darlifarnib; Cabozantinib; Adagrasib,,"Kura Oncology, Inc.",Mirati Therapeutics Inc.,300,2023-10-18,2027-04-05,France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06026410
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed,,Eli Lilly and Company,,1016,2023-12-21,2029-10-05,Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06119581
NCT06128551,"Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,Assigned interventions,,"Revolution Medicines, Inc.",,210,2023-11-14,2026-11-30,France; Germany; Italy; Netherlands; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06128551
NCT06130254,"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Non-small Cell Lung Cancers,Adagrasib; Olaparib,,M.D. Anderson Cancer Center,Mirati Therapeutics Inc.,52,2024-01-30,2030-08-25,United States,No,https://clinicaltrials.gov/study/NCT06130254
NCT06131840,An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms; Pancreatic Ductal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Small Cell Lung Carcinoma",PF-08046050; bevacizumab; 5-Fluorouracil (5-FU); Oxaliplatin; Leucovorin (LV),,"Seagen, a wholly owned subsidiary of Pfizer",Sanofi,914,2023-11-20,2030-09-12,Canada; France; Netherlands; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06131840
NCT06150664,"A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies",Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma,CTX-8371,,Compass Therapeutics,,73,2024-03-19,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT06150664
NCT06162221,A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805,,"Revolution Medicines, Inc.",,616,2024-01-18,2028-12-05,Australia; Denmark; France; Germany; Greece; Italy; Netherlands; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06162221
NCT06162572,"A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC),S095018; S095024; S095029; S095018 Recommended Dose Expansion (RDE); S095024 RDE; S095029 RDE; Cemiplimab,,Servier Bio-Innovation LLC,Institut de Recherches Internationales Servier; Regeneron Pharmaceuticals,176,2024-08-07,2027-07-05,Argentina; Australia; Austria; Belgium; Brazil; France; Hong Kong; Hungary; Italy; Romania; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06162572
NCT06244771,"An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer",FMC-376,,Frontier Medicines Corporation,,403,2024-02-12,2028-04-05,Australia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06244771
NCT06246110,A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer,Phase 2,Recruiting,Interventional,NSCLC,EIK1001; Pembrolizumab; Paclitaxel; Pemetrexed; Carboplatin,,Eikon Therapeutics,,70,2024-02-06,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06246110
NCT06248606,Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; NSCLC; KRAS G12C,Adagrasib; Stereotactic Radiosurgery,,"Ryan Gentzler, MD",Mirati Therapeutics Inc.; University of Virginia,30,2024-08-06,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT06248606
NCT06249282,A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biopsy; Biospecimen Collection; Carfilzomib; Computed Tomography; Echocardiography; Magnetic Resonance Imaging; Sotorasib,,City of Hope Medical Center,National Cancer Institute (NCI),15,2024-04-24,2026-03-19,United States,No,https://clinicaltrials.gov/study/NCT06249282
NCT06252649,"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",Phase 3,Recruiting,Interventional,Metastatic Colorectal Cancer,FOLFIRI Regimen; Sotorasib; Panitumumab; Bevacizumab-awwb,,Amgen,,450,2024-07-17,2031-08-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Czechia; Denmark; Estonia; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06252649
NCT06262321,Phase II Trial of Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax,Phase 2,Recruiting,Interventional,Stage 4 NSCLC; Radiotherapy,Prophylactic Palliative Radiotherapy,,University of Rochester,,48,2024-05-15,2029-02-01,United States,No,https://clinicaltrials.gov/study/NCT06262321
NCT06333951,"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",Phase 1,Recruiting,Interventional,Thoracic Tumors; Non-small Cell Lung Cancer,AMG 193; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib,,Amgen,,500,2024-09-17,2031-10-27,Argentina; Australia; Austria; Belgium; Brazil; Canada; China; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06333951
NCT06343402,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma,BBO-8520; Pembrolizumab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,250,2024-05-22,2028-02-05,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06343402
NCT06345729,"A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Placebo; Pembrolizumab,,Merck Sharp & Dohme LLC,,600,2024-05-24,2031-02-18,Argentina; Australia; Austria; Brazil; Bulgaria; Canada; Chile; China; France; Georgia; Germany; Greece; India; Italy; Japan; Mexico; Netherlands; New Zealand; Philippines; Poland; Romania; South Korea; Spain; Turkey (Türkiye); Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06345729
NCT06403436,"A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Adult Solid Tumor; Adult Disease; Cancer; NSCLC; EGFR; KRAS G12C; Squamous Cell Lung Cancer,TT125-802,,TOLREMO therapeutics AG,,50,2023-11-07,2026-12-05,Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06403436
NCT06412198,"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; KRAS G12C Mutations,Cetuximab; Cemiplimab; Adagrasib,,M.D. Anderson Cancer Center,,31,2024-08-28,2028-03-01,United States,No,https://clinicaltrials.gov/study/NCT06412198
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin,,Pfizer,,330,2024-06-27,2028-09-09,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06447662
NCT06452277,"A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations",Phase 3,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer; HER2 Mutation,BAY2927088; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed,,Bayer,,278,2024-08-28,2029-06-27,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong; Hungary; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Singapore; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06452277
NCT06475807,Cancer Nutrition Study: CaNS - A Pilot Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors,Not Applicable,Recruiting,Interventional,Cancer,High-fermented food; High fiber supplementation,,University of Pittsburgh,,60,2024-07-17,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06475807
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06582771,A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Non Small Lung Cancer,Sotorasib,,Memorial Sloan Kettering Cancer Center,,39,2024-08-30,2026-08-05,United States,No,https://clinicaltrials.gov/study/NCT06582771
NCT06602661,A Prospective Randomized Study of Reinforced Vs Non-reinforced Staple Lines in Fissureless Lobectomy,Phase 1,Not yet recruiting,Interventional,"Lung; Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Lung Cancer, Non-Small Cell; Lung Carcinoma; Lobectomy; Lobectomy Patient; Lobectomy by Video-thoracoscopies; VATS",Fissureless Lobectomy with Reinforced Staple Lines; Fissureless Lobectomy with Non-Reinforced Staple Lines,,Surrey Thoracic Surgery Group,Johnson and Johnson Medical,65,2025-01-01,2028-01-05,Canada,No,https://clinicaltrials.gov/study/NCT06602661
NCT06607185,A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab,,Eli Lilly and Company,,750,2024-10-21,2030-01-05,Belgium; China; France; Germany; Italy; Japan; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06607185
NCT06644768,"A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Lung Cancer,valemetostat tosylate; pembrolizumab,,Daiichi Sankyo,Merck Sharp & Dohme LLC,137,2024-10-30,2030-04-30,Argentina; Brazil; China; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06644768
NCT06660407,Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition,Phase 2,Recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection; Computed Tomography; Immunotherapy; Palliative Radiation Therapy; Spatially-fractionated Radiation Therapy,,Mayo Clinic,,20,2024-11-14,2027-01-10,United States,No,https://clinicaltrials.gov/study/NCT06660407
NCT06667076,"A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Amivantamab; Lazertinib; Chemotherapy: Pemetrexed; Chemotherapy: Carboplatin,,"Janssen Research & Development, LLC",,480,2024-12-16,2030-12-26,Finland; Greece; Israel; Poland; Puerto Rico; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06667076
NCT06712316,"A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Pumitamig; Pembrolizumab; Carboplatin; Pemetrexed; Paclitaxel,,BioNTech SE,Biotheus Inc.,982,2025-01-07,2030-12-05,Australia; Belgium; China; France; Germany; Italy; Poland; Romania; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06712316
NCT06720987,"A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations",Phase 1,Recruiting,Interventional,KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies; CRC (Colorectal Cancer),KQB365; Cetuximab,,Kumquat Biosciences Inc.,,128,2025-02-04,2030-06-30,United States,No,https://clinicaltrials.gov/study/NCT06720987
NCT06730750,"A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,BMS-986490; Bevacizumab,,Bristol-Myers Squibb,,360,2025-02-12,2029-12-09,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06730750
NCT06788912,KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC),Phase 2,Recruiting,Interventional,Lung Neoplasm Malignant,Pembrolizumab (neoadjuvant); Cisplatin; Gemcitabine; Pemetrexed; Sacituzumab tirumotecan; H1 receptor antagonist; H2 receptor antagonist; Acetaminophen (or equivalent); Dexamethasone (or equivalent); Carboplatin; Pembrolizumab (adjuvant); Paclitaxel; Steroid mouthwash (dexamethasone or equivalent),,Merck Sharp & Dohme LLC,,60,2025-03-20,2032-02-06,Chile; Greece; Hungary; Italy; Poland; Spain; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT06788912
NCT06793215,"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin,,Hoffmann-La Roche,Chugai Pharmaceutical,600,2025-10-24,2030-10-31,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Hungary; Italy; Netherlands; New Zealand; Poland; Portugal; Singapore; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06793215
NCT06804824,"A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,VVD-159642; Sotorasib; Trametinib,,"Vividion Therapeutics, Inc.",,220,2025-02-25,2027-08-01,Australia; United States,No,https://clinicaltrials.gov/study/NCT06804824
NCT06807619,BrainMet ADePPT (Anticancer Drug Penetration Platform Trial),Phase 1,Recruiting,Interventional,Brain Tumor,Sotorasib,,Memorial Sloan Kettering Cancer Center,Amgen,16,2025-01-29,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT06807619
NCT06875310,"A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin,,Mirati Therapeutics Inc.,,630,2025-04-24,2032-04-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06875310
NCT06881784,"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",Phase 3,Recruiting,Interventional,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),daraxonrasib; docetaxel,,"Revolution Medicines, Inc.",,420,2025-05-06,2030-12-01,Australia; Belgium; France; Germany; Hong Kong; Ireland; Italy; Japan; Netherlands; Poland; Puerto Rico; Singapore; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06881784
NCT06890598,"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Olomorasib; Pembrolizumab; Durvalumab; Placebo,,Eli Lilly and Company,AstraZeneca,700,2025-03-27,2032-02-05,Australia; Austria; Belgium; Brazil; Chile; China; Czechia; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06890598
NCT06907615,"An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,HLX43 DOSE 1 (2.0 mg/kg); HLX43 DOSE 2 (2.5 mg/kg),,Shanghai Henlius Biotech,Henlius USA Inc.,243,2025-06-09,2028-06-04,China; United States,No,https://clinicaltrials.gov/study/NCT06907615
NCT06917079,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",Phase 1,Recruiting,Interventional,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818; Pembrolizumab; Platinum chemotherapy (cisplatin or carboplatin); Pemetrexed; Cetuximab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,287,2025-03-31,2029-09-05,United States,No,https://clinicaltrials.gov/study/NCT06917079
NCT06945484,PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study,Not Applicable,Not yet recruiting,Interventional,"NSCLC Stage II; NSCLC, Stage III",Precision Exercise Regimen for Cancer Care (PERCC),,University of Utah,,20,2025-12-05,2030-12-05,United States,No,https://clinicaltrials.gov/study/NCT06945484
NCT06975293,"Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer; Metastatic Melanoma; Metastatic Endometrial Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Solid Tumor,STC-15 in combination with toripalimab,,STORM Therapeutics LTD,"Coherus Oncology, Inc.",188,2025-05-05,2026-01-29,United States,No,https://clinicaltrials.gov/study/NCT06975293
NCT06997497,"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)",Phase 3,Recruiting,Interventional,Colon Adenocarcinoma; Rectal Adenocarcinoma,MK-1084; Oxaliplatin; Leucovorin/levofolinate calcium; 5-Fluorouracil; Cetuximab; Bevacizumab; Bevacizumab biosimilar,,Merck Sharp & Dohme LLC,,477,2025-07-16,2030-10-27,Argentina; Australia; Brazil; China; Finland; France; Germany; Hong Kong; Israel; Japan; Netherlands; Poland; Romania; South Korea; Spain; Taiwan; Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06997497
NCT07012031,"A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,Locally Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Sotorasib; Trastuzumab Deruxtecan,,National Cancer Institute (NCI),,37,2026-08-07,2027-06-14,Canada,No,https://clinicaltrials.gov/study/NCT07012031
NCT07023731,"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,KRAS G12D Mutation; Advanced Solid Cancer,ARV-806,,Arvinas Inc.,,159,2025-05-29,2029-04-02,United States,No,https://clinicaltrials.gov/study/NCT07023731
NCT07063745,A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion,Phase 2/Phase 3,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer With MTAP Deletion,BMS-986504; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed; Paclitaxel; Nab-paclitaxel,,Bristol-Myers Squibb,,590,2025-12-30,2031-08-12,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hong Kong; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Norway; Poland; Romania; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT07063745
NCT07090499,A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.,Phase 1,Recruiting,Interventional,"Advanced/Metastatic Solid Tumors; Bladder Cancer; Urothelial Carcinoma; Advanced Non-Small Cell Lung Cancer; Carcinoma, Non Small Cell Lung; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Cancer",PF-08046876,,Pfizer,,310,2025-08-20,2029-07-08,Canada; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT07090499
NCT07094204,A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications,Phase 1,Recruiting,Interventional,Solid Tumor; Non-Small-Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer,ASP5834; panitumumab,,Astellas Pharma Inc,,364,2025-07-25,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT07094204
NCT07190248,"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Pembrolizumab (+) Berahyaluronidase alfa; Pemetrexed; Cisplatin; Carboplatin,,Merck Sharp & Dohme LLC,,675,2025-10-08,2032-08-06,Australia; Austria; Hungary; Israel; Japan; Romania; South Korea; Spain; Taiwan; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT07190248
